xFurther details from the phase 2b AZALEA trial with the factor XI inhibitor abelacimab (Anthos) show significant reductions in major and clinically relevant nonmajor bleeding compared with rivaroxaban for patients with AF; the risk of stroke was moderate to high. The trial was stopped earlier this year because of an “overwhelming” reduction in bleeding with …
Results of a trial using an intensive, 4-year program aimed at blood pressure lowering showed that intervention reduced not only blood pressure (BP), but also significantly reduced the risk of total dementia over that period. All-cause dementia, the primary outcome, was significantly reduced by 15% in the intervention group compared with usual care, and cognitive …
In patients with subclinical atrial fibrillation (AF) detected by implanted devices such as pacemakers or loop recorders, oral anticoagulation with apixaban resulted in a lower risk of stroke or systemic embolism than aspirin, but a higher risk of major bleeding in the ARTESIA study. The results appear to contrast somewhat with the recently reported NOAH-AFNET …